Palleon: Sweeter checkpoints

How Palleon aims to treat cancer by targeting glycan receptors, ligands

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints found on both adaptive and innate immune cells.

Glyco-immune checkpoints are receptors on immune cells that turn cell activation off when they detect the presence of glycan patterns on tumors. Because glyco-immune receptors occur on both innate and adaptive immune

Read the full 749 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE